Molecular Formula | C21H12ClF5N2 |
Molar Mass | 422.78 |
Density | 1.40 |
Melting Point | 93℃ |
Boling Point | 528.4±50.0 °C(Predicted) |
Appearance | powder |
Color | white to beige |
pKa | -1.87±0.30(Predicted) |
Storage Condition | room temp |
In vitro study | LXR-623 inhibits LDLR expression, increases expression of ABCA1 efflux transporters and induces substantial cell death in GBM cells. Brain Metastatic breast cancer cells MDA-MB-361 are highly sensitive to LXR-623-dependent cell death. In GBM cells, LXR-623 inhibited LDL uptake and induced cholesterol efflux, resulting in a significant decrease in intracellular cholesterol content. Normal brain cells are insensitive to LXR-623, probably due to the negative feedback effect that normal cells rely on endogenous cholesterol synthesis to maintain integrity through the synthesis of hydroxysterols. |
In vivo study | LXR-623 is rapidly absorbed in vivo, with peak concentrations (Cmax) occurring approximately 2 hours after administration. The Cmax and the area under the concentration-time curve are proportional to the dose. The average half-life was 41-43 hours. In a LDLr knockout mouse model of atherosclerosis, oral administration of LXR-623 upregulates its intestinal ABCG2 and ABCG2 expression, reducing the burden of atherogenesis, without affecting serum or liver cholesterol and triglycerides. In mice with glioblastoma, LXR-623 had brain permeability and resulted in tumor regression, reduced cholesterol levels and induced cell death. |
UN IDs | UN 2811 6.1 / PGIII |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.365 ml | 11.827 ml | 23.653 ml |
5 mM | 0.473 ml | 2.365 ml | 4.731 ml |
10 mM | 0.237 ml | 1.183 ml | 2.365 ml |
5 mM | 0.047 ml | 0.237 ml | 0.473 ml |
biological activity | LXR-623 (WAY-252623) is a new type of liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β respectively. It has biological oral activity and can pass through the blood-brain barrier. |
target | TargetValue LXR-β 24 nM LXR-α 179 nM |
Target | Value |
LXR-β | 24 nM |
LXR-α | 179 nM |
in vitro study | LXR-623 inhibit LDLR expression, increase ABCA1 efflux transporter expression and induce large-scale cell death of GBM cells. Brain metastatic breast cancer cell MDA-MB-361 is highly sensitive to LXR-623-dependent cell death. In GBM cells, LXR-623 inhibits LDL absorption and induces cholesterol outflow, resulting in a significant decrease in intracellular cholesterol content. Normal brain cells are not sensitive to LXR-623, which may be due to the negative feedback effect that normal cells rely on endogenous cholesterol synthesis and maintain complete through the synthesis of hydroxysterol. |
in vivo studies | LXR-623 can be quickly absorbed in the body, and the peak concentration (Cmax) appears about 2 hours after administration. Cmax and concentration time curve below the product into a dose proportional relationship. The average half-life is 41-43 hours. In a mouse model of LDLr knockout atherosclerosis, oral administration of LXR-623 can up-regulate the expression of ABCG5 and ABCG8 in intestinal tract and reduce the burden of atherosclerosis without affecting serum or liver cholesterol and triglyceride. In mice with malignant gliomas, LXR-623 have brain permeability and cause tumor regression, reduce cholesterol levels and induce cell death. |